Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2004

View Archived Issues

Avanir provides second quarter development highlights

PD-200437 prevents the development of osteoarthritis in vivo

Potent in vivo antinociceptive effects of orally active agent by Mochida

Weight loss and appetite reduction found with Axokine in overweight/obese subjects

ATL-962 reported to reduce body weight of obese patients

Lundbeck highlights recent developments

Pharmacokinetics of vBAFF-R:Fc in healthy mice and a mouse model of arthritis

OGX-O11 potently inhibits clusterin expression in prostate cancer

First randomized trial to confirm Her1/EGFR inhibitor prolongs survival in NSCLC after chemotherapy

Novel orally active antiinflammatory adhesion molecule inhibitor

Quarterly progress at Cytokinetics

MP-1 changes name to Phoenix Biosciences

Wyeth and Karo Bio extend collaboration, advance lead compound

Phase II data supports progression of Onyvax-P for advanced prostate cancer

PRDT's ligand technology binds and removes viruses from blood product

Prosidion to acquire DPP-IV platform from Probiodrug

IPL-512602 fails to meet primary endpoint in asthma study

Enrollment complete in phase IIa trial of DG-031 for heart attack prevention

Guilford licenses U.S. rights to GPI-1485 to Symphony Neuro Development Company

FDA accepts Genmab IND for phase I/II study of HuMax-CD20 in CLL

Further preclinical data on antirheumatic disease activity of AGIX-4207

New antiviral agents prepared and tested at Bayer

Boehringer Ingelheim presents novel xanthine-based DPP-IV inhibitors

AutoVac vaccines designed for inflammatory and bone diseases

Aventis claims new MMP-13 inhibitors and their use

New Akt kinase inhibitors emerge from Merck R&D

Grelan scientists develop new PDE4 inhibitors for use in respiratory disorders

New antimicrobial agents targeting bacterial aminopeptidase bMAP

Quinazoline-based calcilytic agents newly developed at NPS